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What does this study add?
• Acne treatment guidelines published since 2013 were deficient in several key areas, even those developed using the AGREE II instrument.
• They universally lacked adequate stakeholder involvement, transparency and methodological rigour.
• Trustworthiness as defined by the U.S. Institute of Medicine criteria was only partially attained.
• All raised one or more of the red flags of Lenzer et al., indicative of potential bias.
The U.S. Institute of Medicine (IOM) defines clinical practice guidelines (CPGs) as 'statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options'. 1 Clinicians are increasingly relying upon evidence syntheses such as CPGs to enable confident decision-making on the best treatment and long-term management strategies for their patients. Agencies involved with reimbursement policies also often consult guidelines when considering which interventions should qualify.
No acne treatment guideline claimed to be evidence-based until the publication in 2003 of the consensus recommendations of the Global Alliance to Improve Outcomes in Acne. 2 Since then > 20 national and international acne treatment guidelines have been published as journal articles or online resources. In 2014, two appraisals using the Appraisal of Guidelines for Research and Evaluation (AGREE) II Reporting Checklist (hereafter referred to as the AGREE II checklist) were published. [3] [4] [5] Both found that the reporting quality of seven articles identified as CPGs was highly variable, with inconsistent domain scores between and within the guidelines. The underlying methodological quality of CGPs, which may only partially be reflected in AGREE II checklist scores, is generally associated with fulfilment of the IOM's eight criteria of guideline trustworthiness, which are shown in Table 1 together with the corresponding AGREE II checklists items. 1, 3 Our primary objective was to assess how many acne treatment guidelines published following the earlier appraisals had been developed using the AGREE II instrument and to evaluate the effect on reporting quality using the AGREE II checklist. Secondary objectives were to (i) determine to what extent each guideline met the IOM criteria of trustworthiness; (ii) use CheckUp to assess guidelines that had been updated; 6 and (iii) identify the number of red flags of Lenzer et al. per guideline suggestive of potential bias. 7 
Materials and methods
The protocol for this study was published in PROSPERO. 8 
Identification of acne treatment guidelines
Searches were conducted in bibliographic databases and guideline depositories (Table 2) .
They were not language limited but were restricted to the date range 1 January 2013 to 8 December 2016. We also looked for updates of any of the guidelines identified by Kawala et al. or Sanclemente et al., 4, 5 and conducted a Google search for any guidelines not indexed in a database. We included any publication covering a range of different interventions for acne vulgaris written to assist target users in the delivery of care. We excluded publications limited to a single intervention or intervention class, which addressed other types of acne or which had been included in either of the previous appraisals using the AGREE II Reporting Checklist. Two reviewers (E.A.E., Z.F.) scanned titles and abstracts for articles meeting the inclusion criteria; any disagreements were resolved by discussion. The full texts of articles that met the inclusion criteria or upon which a decision could not be made without further information were retrieved.
Appraisal of reporting quality using the AGREE II checklist
The AGREE II checklist comprises 23 items in six domains. Each item is scored on a scale from 1 to 7 (1 = strongly disagree; 7 = strongly agree). Six assessors with a range of expertise (two dermatologists, an acne researcher, a guideline expert, a patient and a lay person, all with knowledge of evidence-based medicine) independently scored the retrieved guidelines. They were provided with the guideline plus any supporting documents and/or related publications. In the case of one guideline adapted from another, the source guideline was also provided. For every item, each assessor was asked to record the rationale for their scores. Differences were resolved by asking those who had provided outlying scores to reassess them. Any remaining discrepancies were resolved by discussion or left unchanged. Standardized domain scores (expressed as percentages) were calculated as described in the AGREE II user's manual. To enable fairer comparisons to be made, we decided not to report actual percentage scores but to use a 5-point Likert scale with the following descriptors: excellent (> 80%), good (> 60-80%), average (> 40-60%), fair (> 20-40%) and poor (≤ 20%). A precedent for categorical reporting of scores was set by Duda et al.
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Assessment of trustworthiness using the U.S. Institute of Medicine criteria Each guideline was assessed by two reviewers (E.A.E., Z.F.) for compliance with the IOM's criteria of trustworthiness using the following categories: fully met, partially met or not addressed. To facilitate equitable appraisal, criterion five (see Table 1 ) was split so that evidence foundations and rating the strength of recommendations were evaluated separately.
Assessment of reporting quality of updated guidelines using CheckUp
CheckUp was designed to assess the reporting quality of updated guidelines and congruence with the parent guideline. 7 It is a 16-item checklist that provides a qualitative assessment rather than a score. Assessments are reported as yes, no, unclear or not applicable. It was applied by two reviewers (E.A.E. and Z.F.) to any of the guidelines that had been updated over the specified time period.
Identification of red flags suggestive of potential bias
Each guideline was evaluated for sources of potential bias according to Lenzer et al. by two reviewers (E.A.E., Z.F.), who assessed the number of red flags, out of a maximum of six. 7 
Results
Search results are summarized in Figure 1 . Seven guidelines fulfilling the eligibility criteria and published after 11 September 2013 were retrieved. [12] [13] [14] [15] [16] [17] [18] This corresponds to the search end date of the second of the earlier appraisals. 4 An additional guideline was identified from internet searches, making a total of eight. 19 Two were updates of existing guidelines. 16, 17, 20, 21 There were five national guidelines (Canadian, 12 Chinese, 18 Spanish, 15 ].
Key characteristics of the guidelines
Four of the guidelines were evidence-based, 12, 16, 17, 19 two of which had been developed using the AGREE II instrument (Table 3) . 12, 16 Two unambiguously assessed benefits and harms in a systematic way and hence fully met the IOM definition of a CPG. 16, 19 The Canadian guideline was adapted from the original European S3 guideline using the ADAPTE Resource Toolkit. 21, 22 Two guidelines were derived from existing guidelines that the developers had not assessed for quality or trustworthiness. 13, 14 All eight guidelines covered multiple interventions for acne or acne vulgaris. Five were directly or indirectly funded by the pharmaceutical industry. [12] [13] [14] [15] [16] When stated (by five of eight guidelines), target users of the guidelines varied from dermatologists only to primary care providers only or a range of healthcare professionals. 12, 14, 16, 19 Stakeholder representation on guideline development groups (GDGs) was universally poor. The GDG for the U.S. guideline had a single patient representative. Patients were not represented on the remaining GDGs with the possible exception of the U.K. guideline for which membership details were not clearly disclosed. In all cases, dermatologists predominated among the GDG membership, again with the possible exception of the U.K. guideline. Further characteristics are shown in Table S1 (see Supporting Information).
Summary of AGREE II checklist scores
The lowest-scoring domains across all eight guidelines (shown in Table 4 ) were applicability (six of eight rated poor, one fair and one average) and rigour (four of eight rated poor, one fair and three average). Only six of the 48 domains of the included guidelines scored above average: three for editorial independence, two for scope/purpose and one for clarity. For the two guidelines that had used the AGREE II instrument during development, there were zero (Canadian) and one (EDF) below-average scores compared with six (SE Asian), five (Chinese and European other), four (Spanish), three (U.S.A.) and one (U.K.) below-average scores for the remaining guidelines.
Appraisal of the guidelines using the U.S. Institute of Medicine's criteria of trustworthiness
We considered the criterion 'establishing transparency' to be fully met if sufficient information had been provided for a third party to be able to repeat the guideline development process. None of the guidelines met all criteria in full ( Table 5 ). The two guidelines that had used the AGREE II instrument during development (the Canadian ones and the EDF) in most cases partially met and occasionally fully met each criterion. The U.S. guideline partially met all but one criterion (external review). Similarly, the U.K. guideline partially or fully met all but one criterion (no rating of strength of recommendations was undertaken). The Chinese guideline failed to address six criteria, and the European (other), SE Asian and Spanish guidelines did not address five. Reasons why ratings of partially met were given are shown in Table S2 (see Supporting Information).
Appraisal of two updated guidelines using CheckUp
The U.S. and EDF updated guidelines were further appraised using the 16-item CheckUp tool. 6 For the updated U.S. guideline, we rated one item as addressed and clear, three items as addressed but unclear, seven items as not addressed and two as not applicable (Table S3 ; see Supporting Information). As the guideline was produced by the American Academy of Dermatology (AAD) for the AAD, there was no external funder (item 9) and no external review (item 14). For the updated EDF guideline, we rated five items as addressed and clear, seven items as addressed but unclear and four items as not addressed (Table S4 ; see Supporting Information). 
Number of red flags per guideline
A completely trustworthy guideline should have no red flags. We associated one or more red flags with each of the eight guidelines (Table 6 ). Six had red flags for types of sponsorship, six for conflicts of interest (COI), four for inadequate involvement of methods experts, six for lack of external review and five for inadequate stakeholder representation on the GDG. There was no evidence of any guideline intentionally 'stacking' the composition of the GDG. Three guidelines had five red flags. [13] [14] [15] It is possible that the U.K. guideline may have had many more than the one it received, but it proved impossible to assess owing to nondisclosure of information.
Discussion
As healthcare practitioners increasingly rely upon evidence summaries to guide their clinical decision-making, CPGs have become a well-recognized way of articulating recommendations based upon a synthesis of the best-available evidence combined with stakeholder consensus. However, treatment guidelines may or may not always fulfil the definition of a CPG and there is no easy and reliable way for end users to identify trustworthy guidelines that have been developed through a process involving a rigorous systematic review and quality appraisal of the available evidence. While we may be challenged for applying the AGREE II checklist to guidelines that were not specifically designated as being evidence-based by their developers, our justification for doing so was to enable direct comparisons of reporting quality to be made and for readers to judge to what extent nonevidence-based guidelines can play a role in informing improved patient care. When Sanclemente et al. conducted the first critical appraisal of acne CPGs published between July 2002 and July 2012, 5 they identified six acne treatment guidelines that fulfilled their definition of a CPG (must be evidence based) and 12 that did not. Our more recent searches identified eight treatment guidelines published subsequently, between September 2013 and December 2016, of which half were explicitly evidence based. While there has been a substantial increase in the number of acne treatment guidelines developed and published over the last 3 years when compared with the previous decade, there appears to have been very limited increase in guideline quality. Our domain scores using the AGREE II checklist were uniformly disappointing for all eight guidelines. The best three guidelines included two that had used the AGREE II instrument in their development (the Canadian one and the EDF) plus the U.K. guideline, but they did not score as well as might be expected. Kawala et al. and Sanclemente et al., 4, 5 reported several higher AGREE II domain scores for the original EDF guideline than we assigned to the updated version. To ensure a broader evaluation, we used additional methods alongside the AGREE II checklist, all of which showed similar trends. The EDF recently appraised the reporting quality of its own guidelines using the AGREE II instrument, 23 and found Based on reviews of existing guidelines, which were not assessed for quality or trustworthiness.
considerable heterogeneity between them. The original EDF acne guideline was among the four best scoring of the 25 guidelines assessed, 19 with scores for five of six domains higher than ours for the updated version.
We recognize that part of the AGREE II process requires assessors to make an independent judgement of each guideline that includes a global quality score and a choice from one of three options regarding recommendation of the guideline (yes, yes with modifications or no). We elected not to do this because each guideline had diverse strengths and weaknesses that an overall recommendation was unlikely to reflect. We also noted that the AGREE II user's manual states 'The six domain scores are independent and should not be aggregated into a single quality score'. This conflicts with the request to generate a global score after assessment as no advice is given about the relative weightings of the six different domains.
The AGREE tool was first released in 2003 and has undergone several refinements. However, the impact on the robustness of development and reporting quality of acne treatment guidelines has been disappointing. The failure of most acne guideline developers to use this tool to ensure methodological rigour is somewhat puzzling and may, in part, reflect shortcomings within the tool itself. We found use of the checklist somewhat challenging, the main reasons being a degree of overlap and repetition of criteria across items (e.g. target population appears in four items), ambiguity about which score to give when it was unclear what had been done and lack of clarity concerning the requirements for a high score. For example, the IOM trustworthiness criteria suggest that only a minority of GDG members should have COI and yet this is not reflected anywhere in the guidance for item 23 in the AGREE II tool. For the same item, the appraiser requires detailed information on which types of COI should have been considered and which methods for identifying and reporting them are deemed appropriate before being able to score it correctly. We noted, but were uncertain how to address, inconsistent reporting of financial links between the GDG members and industry. The required level of detail to enable accurate scoring is missing in the AGREE II user's manual for this and several other items. Furthermore, assessing reporting quality with the AGREE II checklist may only partially reveal underlying methodological rigour. As an illustration, it would be possible to score full marks for the item 'search methods' even if inadequate search terms had been used within a single database as long as the time period was specified and the search strategy provided.
While the AGREE II checklist is widely recognized and frequently used to assess guidelines for reporting quality, numerous other instruments are available which seek to promote and/or assess methodological quality. 24 Some of these were considered by us as an additional appraisal tool and discounted. Instead, we elected to adopt the IOM criteria of trustworthiness as a complementary means of assessment. 25 Across all eight guidelines, very few IOM criteria were fully met such that no guideline could be regarded as highly trustworthy based on those criteria. One of the key findings of this evaluation of CPGs was the nonadoption of the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach, 26 which is increasingly accepted as a formal and reliable method of moving from evidence to recommendations in guideline development. 27 The red flags of Lenzer et al. provide a convenient mechanism for identifying potential bias with respect to GDG composition, sponsorship, COI and external review. 7 Applying these criteria highlighted an almost total lack of patient involvement (also identified using the AGREE II checklist). This is troubling, not because the World Health Organization, IOM, G-I-N and AGREE II recommend such engagement, 1, 3, 28, 29 but because CPGs are the linchpin between evidence-based medicine and evidence-based practice (EBP). EBP incorporates by definition patient values and preferences, 30 with CPGs enabling confident and reliable shared decisionmaking between the treating physician and the patient. Also, it is inherently different when patients (or their representatives) are fully part of guideline development, because then it is not only about the patient, it is with the patient. We recognize that engaging patients can be challenging; 31 nevertheless, it should be pursued as vigorously as possible as optimized outcomes -the main goal of CPGs -can rarely be achieved without their input. Although only a few classes of drug are used to treat acne vulgaris, they can be prescribed in numerous different twoor three-way combinations, most of which have never been compared in randomized controlled trials. This results in significant evidence gaps and makes formulating any comprehensive guideline for acne difficult, even before other types of intervention (e.g. physical therapies, cosmetic remedies, skin care regimens) are considered. Furthermore, there is a paucity of rigorous systematic reviews of acne therapies, which means that guideline developers often have to rely on the primary evidence, thereby increasing the workload considerably. Until more high-quality systematic reviews and meta-analyses of acne therapies become available, producing guidelines that are narrower in scope and focus on one intervention type may be a better strategy, in order to reduce the workload of the GDG.
Given the apparent low adoption rate of the AGREE II instrument and the uncertainty of its impact on quality, what steps can be taken to improve acne treatment guidelines? We make the following suggestions based upon our findings. (i) Always include patients, target audience members, other relevant stakeholders (e.g. trial sponsors) and methods experts in the GDG, give them an equal voice and involve them in all stages of the development process. (ii) If a guideline is not evidence-based, state clearly why a nonevidence-based guideline is necessary; use terminology in the title and abstract that clearly distinguishes such a guideline from a CPG and provide greater transparency about the approach adopted to formulate the recommendations. (iii) Justify use of selected efficacy outcomes if not all available outcomes are included as evidence. (iv) Always adopt validated methods such as GRADE for rating the quality of the evidence and the detection of potential bias. (v) Link recommendations to publications from which data were extracted such that target audience members can access the evidence should they wish to do so. (vi) Give equal consideration to the benefits and harms of included interventions and ensure recommendations clearly take account of both. (vii) Pay greater attention to potential COI, especially when funding for guideline development has been provided by interested parties such as product manufacturers; check disclosures for inconsistencies or omissions (e.g. payment for services provided) and consider recusal to avoid potential bias. Follow recommendations to limit the number of conflicted members of the development group. 1, 7 (viii) Recognize that independent external review is an integral and essential part of the development process; invite critical review by all stakeholder groups and anyone who wishes to comment, and report the results in the main guideline document. In summary, we have used a variety of tools to show that recent acne treatment guidelines lack transparency, methodological rigour and stakeholder participation. Furthermore, they may not be entirely free from bias. We have proposed eight actions that, if addressed in full, should increase guideline trustworthiness and user confidence. The British Association of Dermatology now mandates stringent requirements for guideline developers, including adoption of the GRADE approach. 32 If other institutional guideline sponsors and journal editors also raise the bar, a new era of more trustworthy guidelines may be about to begin.
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